Abstract
Metabolic acidosis is a common complication in patients with chronic kidney disease (CKD). Its consequences on the function of organ systems are numerous and mostly negative.
Acidosis worsens the prognosis of patients with CKD. Non-randomized studies have shown relatively good effects in the treatment of acidosis, but these have mostly failed to reproduce in randomized trials.
Standard bi-carbonate treatment has negative consequences, especially an unwanted supply of sodium or potassium. Recently, there has been an effort to find new substances, in the advanced phase of clinical trials there is a veverimer.